moa of semaglutide A new era for oral

Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline

A class of drugs known as glucagon-like peptide 1 (GLP-1) agonists, developed 20 years ago to treat diabetes, hit the market rebranded as weight-loss drugs

The risk appears to be rare, and the evidence is not fully settled

What evidence supports the effectiveness of GLP-1 medications in reducing alcohol consumption

In a statement, Novo Nordisk, maker of the GLP-1 drug semaglutide, noted, For Wegovy specifically, animal studies suggest there may be risks to the fetus, and weight loss during pregnancy offers no benefit and may cause harm